A Reduction of Calcineurin Inhibitors May Improve Survival in Patients with De Novo Colorectal Cancer after Liver Transplantation

• Published in: Medicina (Kaunas, Lithuania) Vol. 58; no. 12; p. 1755
• Main Authors: Ossami Saidy, Ramin Raul, Wegener, Elisa, Uluk, Deniz, Dittrich, Luca, Schöning, Wenzel, Lurje, Georg, Öllinger, Robert, Modest, Dominik Paul, Tacke, Frank, Haase, Oliver, Pratschke, Johann, Eurich, Dennis
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 29.11.2022; MDPI
• Subjects: Calcineurin Inhibitors - therapeutic use; Cancer therapies; Care and treatment; Chemotherapy; Classification; Colorectal cancer; colorectal carcinoma; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - surgery; de novo malignancy; Development and progression; Graft rejection; Histopathology; Humans; immunosuppression; Immunosuppressive Agents - therapeutic use; Immunotherapy; Incidence; Inflammatory bowel disease; Laboratories; Liver; Liver cancer; Liver diseases; Liver Transplantation; Liver transplants; Patient outcomes; Patients; Prevention; Radiation therapy; Retrospective Studies; Risk Factors; Surveillance; Transplantation; Germany; immunosuppression; de novo malignancy; colorectal carcinoma; liver transplantation
• ISSN: 1648-9144; 1010-660X; 1648-9144
• DOI: 10.3390/medicina58121755

Background and Objectives: After liver transplantation (LT), long-term immunosuppression (IS) is essential. IS is associated with de novo malignancies, and the incidence of colorectal cancer (CRC) is increased in LT patients. We assessed course of disease in patients with de novo CRC after LT with focus of IS and impact on survival in a retrospective, single-center study. Materials and Methods: All patients diagnosed with CRC after LT between 1988 and 2019 were included. The management of IS regimen following diagnosis and the oncological treatment approach were analyzed: Kaplan−Meier analysis as well as univariate and multivariate analysis were performed. Results: A total of 33 out of 2744 patients were diagnosed with CRC after LT. Two groups were identified: patients with restrictive IS management undergoing dose reduction (RIM group, n = 20) and those with unaltered regimen (maintenance group, n = 13). The groups did not differ in clinical and oncological characteristics. Statistically significant improved survival was found in Kaplan−Meier analysis for patients in the RIM group with 83.46 (8.4−193.1) months in RIM and 24.8 (0.5−298.9) months in the maintenance group (log rank = 0.02) and showed a trend in multivariate cox regression (p = 0.054, HR = 14.3, CI = 0.96−213.67). Conclusions: Immunosuppressive therapy should be reduced further in patients suffering from CRC after LT in an individualized manner to enable optimal oncological therapy and enable improved survival.